The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 4, 2015, Pages 862-869

  Liu, Li Ting ^a   Tang, Lin Quan ^a   Chen, Qiu Yan ^a   Lu, Zhang ^a   Guo, Shan Shan ^a   Guo, Ling ^a   Mo, Hao Yuan ^a   Zhao, Chong ^a   Guo, Xiang ^a   Cao, Ka Jia ^a   Qian, Chao Nan ^a   Zeng, Mu Sheng ^a   Bei, Jin Xin ^a   Hong, Ming Huang ^a   Shao, Jian Yong ^a   Sun, Ying ^a   Ma, Jun ^a   Mai, Hai Qiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DNA; MULTIVARIANT ANALYSIS; PATIENT TREATMENT; TUMORS;

CONCURRENT CHEMORADIATION; DISEASE PROGRESSION; MULTI VARIATE ANALYSIS; NASOPHARYNGEAL CARCINOMA; NEOADJUVANT CHEMOTHERAPIES; PROGNOSTIC FACTORS; PROGRESSION FREE SURVIVAL; RISK STRATIFICATION;

DIAGNOSIS;

CISPLATIN; FLUOROURACIL; VIRUS DNA; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONCURRENT CHEMORADIATION THERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISTANT METASTASIS FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; ADJUVANT THERAPY; ANALYSIS OF VARIANCE; BLOOD; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; TIME; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; FLUOROURACIL; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; PROGNOSIS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84948444323     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.08.003     Document Type: Article

References (35)

1. . Choa G. Nasopharyng eal carcinoma. Some observations on the clinical features and technique of examination. Pac Med Surg 1967;75: 172-174.
2. . Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011;30:114-119.
3. . Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III rando mized intergroup study 0099. J Clin Oncol 1998;16: 1310-1317.
4. . Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharynge al carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-637.
5. . Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplat in, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:4305-4313.
6. . Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-249.
7. . Airoldi M, Gabriele P, Gabriele AM, et al. Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2011;67:1027-1034.
8. . Bossi P, Orlandi E, Bergamini C, et al. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensitymodulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasophary ngeal cancer. Ann Oncol 2011;22: 2495-2500.
9. . OuYang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-Analysis of pu blished literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146.
10. . Boscolo-Rizzo P, Tirelli G, Mantovani M, et al. Non-endemic locoregionally advanced nasopharyngeal carcino ma: Long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice. Eur Arch Otorhinolaryngol 2014 Nov 4 [Epub ahead of print].
11. . Sun X, Zeng L, Chen C, et al. Comparing treatment outcomes of different chemotherapy sequences during intensity modulated radiotherapy for advanced N-stage nasopharyngeal carcinoma patients. Radiat Oncol 2013;8:265.
12. . Sun X, Su S, Chen C, et al. Long-term outcomes of intensitymodulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities. Radiother Oncol 2014;110:398-403.
13. . Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-1191.
14. Chan KC,Hung EC,Woo JK,et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program Cancer 2013 119 1838-1844.
15. . Lin JC, Wang WY, Chen KY , et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-2470.
16. . Chan AT, Lo YM, Zee B, et al. Plasma Eps tein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-1619.
17. . Hou X, Zhao C, Guo Y, et al. Different clinica l significance of preand post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol 2011; 23:128-133.
18. . Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer 2013;119:963-970.
19. . Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16:1016-1024.
20. . Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast perce ntage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001;18:187-191.
21. . Picci P, Rougraff BT, Bacci G, et al. Prognostic signif icance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-1769.
22. . Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161.
23. . Rosen G, Caparros B, Groshen S, et al. Primary osteogenic sarcoma of the femur: A model for the use of preoperative chemotherapy in high risk malignant tumors. Cancer Invest 198 4;2:181-192.
24. . Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-Adjuvant to induction-concurrent chemoradiotherapy, chan ging from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer 2015;121:1328-1338.
25. . Lee AW, Lau KY, Hung WM, et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol 2008;87:204-210.
26. . Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensitymodulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: Experience of 370 consecutive cases. BMC Cancer 2010;10:39.
27. Yu Z, Luo W, Zhou QC, et al. Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary l ocoregionally advanced nasopharyngeal carcinoma. Chin J Cancer 2009;28:1132-1137.
28. . Leung SF, Chan KC, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advancedstage nasopharyngeal carcinoma. Ann Oncol 2014;25:1204-1208.
29. . Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
30. . Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): A phase 2 multi-institutional trial. Lancet Oncol 2012;13:172-180.
31. Masmoudi A, Toumi N, Khanfir A, et al. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. Cancer Treat Rev 2007;33:499-505.
32. . Gottschalk S, He slop HE, Rooney CM. Adoptive immunotherapy for EBV-Associated malignancies. Leuk Lymphoma 2005;46:1-10.
33. . Li J, Chen QY, He J, et al. Phase I trial of adoptively transferred tumor-infi ltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology 2015;4:-976507.
34. . Chua DT, Ma J, Sham JS, e t al. Long-term survival after cisplatinbased induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. J Clin Oncol 2005;23:1118-1124.
35. . Fountzi las G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study condu cted by the Hellenic Cooperative Oncology Group (HECOG) with biomarker evaluation. Ann Oncol 2012;23:427-435.